The development of allogeneic CAR-T therapies requires efficient, scalable manufacturing processes that reduce manual intervention and minimize open handling.
In this webinar, we’ll explore the development of an integrated manufacturing workflow combining automated cell processing, gene editing, cell expansion, and final product processing.
A key focus will be a novel low-volume harvest strategy that enables direct transfer into the MaxCyte® ExPERT GTx® workflow using sterile-welded connections, eliminating a previously required open-manipulation step.
The presentation will also highlight key process development considerations, including:
- Cell recovery and viability
- Gene-editing efficiency
- Workflow integration
- Scalability
Together, these results demonstrate an integrated, functionally closed approach that streamlines allogeneic CAR-T manufacturing, improves reproducibility, and reduces open handling.
Join the free webinar with certification of attendance.
Attend the Webinar to Learn:
- How automated cell processing, gene editing, expansion, and final product processing can be integrated into an allogeneic CAR-T manufacturing workflow
- How the MaxCyte® ExPERT GTx® can be integrated with upstream and downstream platforms using sterile-welded connections
- How a novel low-volume cell harvest strategy enabled direct transfer into the MaxCyte® GTxTM workflow
- How eliminating a manual open-manipulation step can help streamline manufacturing and reduce opportunities for process variability
This Webinar is Ideal For:
- Cell Therapy Process Development Scientists & Engineers
- Cell Therapy Manufacturing Scientists & Engineers
- CAR-T Cell Therapy Scientists
- Gene Editing Scientists
- Cell Processing Scientists
- MSAT Scientists & Engineers
- CMC Scientists & Managers
- Cell Therapy Manufacturing & Operations Leaders
- R&D and Translational Research Scientists
- Cell & Gene Therapy Program Leaders
Meet the Webinar Speakers
Marina Cortijo Gutiérrez, PhD, is a biomedical researcher specializing in CAR-T cell engineering, gene editing, and advanced cell therapy manufacturing. She completed her PhD in Biomedicine at the University of Granada, focusing on CRISPR/Cas9-based strategies to improve CAR-T cell therapies. Her current work focuses on the development and validation of scalable manufacturing processes for allogeneic CAR-T cells, with particular emphasis on automation, gene editing, and process integration. She has extensive hands-on experience in CAR-T manufacturing, genome editing, and the translation of research workflows toward ATMP-compatible processes.
After her Biology studies in Barcelona, Alicia did her PhD and Postdoc ad the German Cancer Research Institute (DKFZ) developing episomal DNA vectors to engineer stem cells for therapeutic purposes. After that, she joined MaxCyte in 2020 as Field Application Scientist supporting customers across EU develop their cell therapy and bioprocessing workflows.